October 6, 2026
Tony Jones CEO, One Nucleus
Welcome to the Autumn eNews edition from One Nucleus. Autumn seems to get a mixed reputation. Some suffer from the decreased daylight, the frights of Halloween and loud bangs of November 5th. Others welcome the transition to the cosy evening meetings, October treats and spectacular fireworks, all leading to Thanksgiving and then Christmas. Whilst for some, it feels little is changing enough in the sector as investment remains selective and later-stage, and times are tough.
We need change! One Nucleus embraces the…
LONDON, UK; HELSINKI, FINLAND; and NAPLES, ITALY – October 6, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Valo Therapeutics Group ("Valo Therapeutics") and is pleased to announce the placement of Carlos de Sousa, M.D., MBA, as Chief Executive Officer.Valo Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for cancer. The Company's proprietary PeptiCRAd platform combines oncolytic adenoviruses with tumor-associated peptides to…
Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.
Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase 1/2 clinical trial of ORIC-259, including CTA-enabling studies, for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties. Cancer Research Horizons, Cancer…
Four sessions across twodays focusing on key drug discovery and development application areas of organ-on-a-chip technologies
Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, including Novo Nordisk, Bristol Myers Squibb, and Pharmaron
Cambridge, UK, 1st October 2026: CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more confident decision-making, today announced the full scientific programme for the 2026 ‘From Insight to Decision’ e-Symposium. Taking place…
Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation in Clinical Study
— Proprietary algorithm optimized tablet composition and dose level for clinical study in healthy participants —
— Interim results suggest significant potential for developing optimized formulations with fewer clinical rounds —
NOTTINGHAM, England – September 17, 2026 – Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), today reported interim results from a clinical study in which a proprietary artificial intelligence (AI) algorithm selected…
Global drug development consultancy Boyds has strengthened its award-winning Regulatory Affairs team with the appointment of two senior specialists, further expanding its ability to support life sciences companies as they navigate increasingly complex regulatory pathways.
Established in 2005, Boyds works with an international client base to help translate scientific innovation into medicines and medical devices for patient benefit.
Vicki Hayes joins Boyds as Vice President of Regulatory Affairs and Jan Ohotski joins as Director of Regulatory Affairs. Together, they bring senior expertise…
One Nucleus is pleased to announce the shortlist for the One Nucleus Awards 2026.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision, and enabling support across the stakeholders.Best Preclinical Stage R&D Company of the Year:⭐ Axiom Therapeutics⭐ LinkGevity⭐ Immutrin⭐C-Further⭐Asgard TherapeuticsBest Clinical Stage R&D Company of the Year:⭐ CellCentric⭐ Alchemab Therapeutics Ltd⭐ Hemab Therapeutics⭐ Muna Therapeutics⭐ Resolution TherapeuticsBest Use of Emerging Technology of the Year:⭐ deepmirror⭐ Luvida⭐ ExpressionEdits…
Pivotal, which specializes in developing and managing clinical trials for the pharmaceutical and biotechnological industry, receives this recognition for the strength of its management model, the quality of its processes, and its commitment to scientific innovation.
Madrid, September 24, 2026 — The Comunidad de Madrid regional government has awarded the Madrid Excelente quality seal to Pivotal, Spain's first CRO (Clinical Research Organisation), in recognition of a management model built on quality, scientific rigor, and innovation. The distinction cements Pivotal's position as one of the…
Delivering reduced hands-on time, more consistent results and higher sample throughout
Oxford, UK, 24th September.
OGT, a leading global provider of genomic research and diagnostic solutions today unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq™ NGS portfolio, compatible with the Hamiton NGS STAR Line. The latest advancement in OGT’s ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets.
Rising sample volumes are putting clinical research labs under pressure. Maintaining consistent…
Amsbio announce a new partnership with Atelerix to introduce its patented hydrogel technology for the room-temperature storage and transportation of living cells, tissues, organoids and viruses.
Preserving cell functionality during storage and transportation is challenging for cell-based therapies as cryopreservation methods can compromise cell viability and functionality. The novel hypothermic hydrogel technology, available from Amsbio, offers a revolutionary alternative, addressing many of the issues associated with cryopreservation.
This seaweed-derived hydrogel forms a protective…